文献速递乳房整形与再造

既往放疗患者I期假体乳房重建中ADM术后并发症的倾向评分匹配分析

Postoperative complications of ADM use in previously irradiated patients during stage I of implant-based breast reconstruction: A national database propensity score-matched analysis.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2025-02-25

基于MarketScan数据库2012-2020年1234例匹配患者,比较既往放疗后I期假体乳房重建使用与不使用脱细胞真皮基质(ADM)的90天并发症。ADM组伤口愈合问题(8.5% vs 7.8%)和组织坏死(5.5% vs 4.0%)数值较高但无统计学差异,血清肿、血肿、脂肪坏死、感染亦无显著差异。ADM使用与需影像引导引流血肿或血清肿的几率显著降低相关(OR 0.11,95%CI 0.01-0.89,p=.039)。

要点

  • 匹配后ADM组与非ADM组各617例,90天并发症率无显著差异。
  • ADM组伤口问题8.5% vs 7.8%、组织坏死5.5% vs 4.0%,均未达统计学显著。
  • ADM使用与需影像引导引流血肿或血清肿的几率显著降低相关(OR 0.11)。

核心结论

  • 大规模数据中,既往放疗乳腺癌患者使用与不使用ADM的并发症率无显著差异,即使ADM使用随时间增加。
  • ADM的应用应平衡成本、外科医生偏好和美学效果,其在各种重建平面中的作用和成本影响需进一步研究。

研究设计与样本

  • 利用Merative MarketScan研究数据库2012-2020年数据,纳入既往放疗后接受门诊I期假体乳房重建(胸前或胸肌下)的患者。
  • 按ADM使用分层并进行倾向评分匹配,分析90天内术后并发症和额外外科干预,采用多变量逻辑回归。
  • 匹配后共1234例患者,ADM组617例,非ADM组617例。

主要发现

  • ADM使用首次记录于2012年,其频率在研究期间呈正相关(r=0.214,p<.001)。
  • ADM组伤口问题发生率8.5% vs 非ADM组7.8%,组织坏死5.5% vs 4.0%,差异均无统计学意义。
  • ADM组与非ADM组在血清肿形成、血肿、脂肪坏死或术后感染率方面无显著差异。
  • ADM使用与需影像引导引流血肿或血清肿的几率显著降低相关(OR 0.11,95%CI 0.01-0.89,p=.039)。

临床怎么用

  • 原文结论未据此给出推荐。
  • 作者认为ADM的应用应平衡成本、外科医生偏好和美学效果,其在各种重建平面中的作用和成本影响需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acellular dermal matrix (ADM) is widely used in implant-based reconstruction to prevent capsular contracture, but its safety in irradiated patients is underexplored. We aimed to evaluate postoperative complications associated with ADM use in stage I of implant-based breast reconstruction in patients with premastectomy radiation. METHODS: Using the Merative MarketScan Research Databases, 2012-2020, previously irradiated patients undergoing outpatient stage I implant breast reconstruction (prepectoral and submuscular) were stratified by ADM use and propensity score-matched. Postoperative complications and additional surgical interventions within 90 days were analyzed using multivariate logistic regression. RESULTS: Among 1234 matched patients (617 ADM and 617 non-ADM), ADM use was first recorded in 2012, and its frequency showed a positive correlation over the study (r = 0.214, p <.001). Patients with ADM experienced higher rates of wound (8.5% vs. 7.8%) and tissue necrosis (5.5% vs. 4.0%) than non-ADM patients, but these differences were not statistically significant. Additionally, no significant differences were observed between ADM and non-ADM groups in the rates of seroma formation, hematoma, fat necrosis, or postoperative infections. ADM use was associated with significantly lower odds of requiring image-guided fluid drainage for hematomas or seromas (OR 0.11, 95% CI 0.01-0.89, p =.039). CONCLUSION: No significant difference in complication rates was found between previously irradiated breast cancer patients with and without ADM on a large scale, even with ADM usage increasing over time. Its adoption should balance cost, surgeon preferences, and esthetic outcomes, with further research needed on its role in various reconstruction planes and cost impacts.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Lakhlani D, Lin E, Kruayatidee A, et al. Postoperative complications of ADM use in previously irradiated patients during stage I of implant-based breast reconstruction: A national database propensity score-matched analysis. J Plast Reconstr Aesthet Surg. 2025. PMID: 40138755. doi:10.1016/j.bjps.2025.02.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。